- Home
- PRAA vs REPL Comparison
PRAA vs REPL Comparison
Compare PRAA & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAA
- REPL
- Stock Information
- Founded
- PRAA 1996
- REPL 2015
- Country
- PRAA United States
- REPL United States
- Employees
- PRAA N/A
- REPL N/A
- Industry
- PRAA Finance: Consumer Services
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- PRAA Finance
- REPL Health Care
- Exchange
- PRAA Nasdaq
- REPL Nasdaq
- Market Cap
- PRAA 790.6M
- REPL 851.0M
- IPO Year
- PRAA N/A
- REPL 2018
- Fundamental
- Price
- PRAA $19.01
- REPL $7.42
- Analyst Decision
- PRAA Strong Buy
- REPL Strong Buy
- Analyst Count
- PRAA 2
- REPL 6
- Target Price
- PRAA $32.00
- REPL $20.00
- AVG Volume (30 Days)
- PRAA 355.3K
- REPL 755.6K
- Earning Date
- PRAA 05-05-2025
- REPL 05-15-2025
- Dividend Yield
- PRAA N/A
- REPL N/A
- EPS Growth
- PRAA N/A
- REPL N/A
- EPS
- PRAA 1.79
- REPL N/A
- Revenue
- PRAA $1,114,524,000.00
- REPL N/A
- Revenue This Year
- PRAA $7.67
- REPL $31.16
- Revenue Next Year
- PRAA $5.67
- REPL N/A
- P/E Ratio
- PRAA $11.61
- REPL N/A
- Revenue Growth
- PRAA 38.87
- REPL N/A
- 52 Week Low
- PRAA $18.09
- REPL $4.92
- 52 Week High
- PRAA $28.64
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- PRAA 40.79
- REPL 19.56
- Support Level
- PRAA $20.20
- REPL $10.17
- Resistance Level
- PRAA $22.01
- REPL $10.78
- Average True Range (ATR)
- PRAA 0.74
- REPL 0.64
- MACD
- PRAA 0.06
- REPL -0.32
- Stochastic Oscillator
- PRAA 12.15
- REPL 0.84
About PRAA PRA Group Inc.
PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.